TL;DR: The Centers for Medicare & Medicaid Services modified NCD 279 governing deep brain stimulation for essential tremor and Parkinson's disease, with an effective date of January 9, 2026. Here's what billing teams need to know before submitting claims.
CMS deep brain stimulation coverage policy under NCD 279 has been updated. This modification clarifies medical necessity criteria, patient eligibility thresholds, provider qualifications, and exclusion conditions for thalamic VIM, STN, and GPi DBS procedures. No specific CPT or HCPCS codes are listed in the policy document — your team will need to confirm codes with your Medicare Administrative Contractor. Deep brain stimulation billing requires tight documentation alignment with these criteria, or you will see claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Deep Brain Stimulation for Essential Tremor and Parkinson's Disease |
| Policy Code | NCD 279 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | High |
| Specialties Affected | Neurosurgery, Neurology, Movement Disorder Clinics, Hospital Outpatient, Inpatient Facilities |
| Key Action | Audit patient selection documentation against updated VIM, STN, and GPi criteria before billing any DBS implantation claim |
CMS Deep Brain Stimulation Coverage Criteria and Medical Necessity Requirements 2026
CMS deep brain stimulation coverage policy under NCD 279 in the NCD 279 CMS system sets separate, distinct criteria depending on the brain target and the underlying diagnosis. Get these mixed up and your claim fails on medical necessity grounds before a reviewer even reads the rest of the file.
For thalamic VIM DBS — essential tremor and Parkinsonian tremor:
CMS covers unilateral or bilateral VIM DBS for ET or tremor-dominant Parkinson's disease. The patient must meet all three of the following:
| # | Covered Indication |
|---|---|
| 1 | Diagnosis of ET based on postural or kinetic hand tremors without other neurologic signs, OR idiopathic PD with at least two cardinal features (tremor, rigidity, or bradykinesia) that is tremor-dominant in presentation. |
| 2 | Marked disabling tremor rated at least level 3 or 4 on the Fahn-Tolosa-Marin Clinical Tremor Rating Scale — or an equivalent validated scale — in the extremity targeted for treatment. The tremor must cause significant limitation in daily activities despite optimal medical therapy. |
| 3 | The patient must be willing and able to cooperate during a conscious operative procedure, and through all post-surgical evaluations, medication adjustments, and stimulator programming. |
All three criteria must be documented. One missing element means the claim lacks medical necessity support.
For STN or GPi DBS — Parkinson's disease:
CMS covers unilateral or bilateral STN or GPi DBS for PD when the patient meets all five of the following:
| # | Covered Indication |
|---|---|
| 1 | Diagnosis of idiopathic PD with at least two cardinal features (tremor, rigidity, or bradykinesia). |
| 2 | Advanced idiopathic PD, documented using the Hoehn and Yahr staging scale or UPDRS Part III motor subscale scores. |
| 3 | L-dopa responsiveness with clearly defined "on" periods — this must be documented in the clinical record, not assumed. |
| 4 | Persistent disabling symptoms or drug side effects — specifically dyskinesias, motor fluctuations, or disabling "off" periods — despite optimal medical therapy. |
| 5 | Willingness and ability to cooperate during the conscious operative procedure and all post-surgical follow-up. |
The L-dopa responsiveness requirement is the one most often under-documented. If your clinical team hasn't explicitly recorded "on" and "off" periods with a formal levodopa challenge or documented response history, your claim will struggle under medical necessity review.
FDA device requirement:
CMS will only consider a DBS device reasonable and necessary if it is FDA-approved for DBS use, or if it is used under an FDA-approved Category B Investigational Device Exemption (IDE) protocol. Off-label device use outside of an approved IDE trial is not covered. Document the device's FDA approval status in the implant record.
Prior authorization:
NCD 279 does not explicitly list prior authorization requirements at the national level. However, your Medicare Administrative Contractor may impose additional prior auth steps through a local coverage determination. Check with your MAC before scheduling implantation to confirm whether prior authorization is required in your region.
CMS Deep Brain Stimulation Exclusions and Non-Covered Indications
CMS is direct about what disqualifies a patient. This coverage policy lists six absolute exclusions. Any one of them makes DBS not reasonable and necessary — and not reimbursable under Medicare.
| # | Excluded Procedure |
|---|---|
| 1 | Non-idiopathic Parkinson's disease or "Parkinson's Plus" syndromes — Multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome, and similar conditions are not covered under this policy. |
| 2 | Cognitive impairment, dementia, or depression that would be worsened by DBS or would interfere with the patient's ability to benefit from the procedure. |
| 3 | Current psychosis, alcohol abuse, or other drug abuse. |
| 4 | Structural lesions — including basal ganglionic stroke, tumor, or vascular malformation — as the etiology of the movement disorder. |
| 5 | Previous movement disorder surgery within the affected basal ganglion. |
| 6 | Significant medical, surgical, neurologic, or orthopedic comorbidities that contraindicate DBS surgery or stimulation. |
These exclusions are claim denial triggers. If any of these appear in the patient's medical record and the claim goes out anyway, you are looking at a denial — and potentially a recovery audit flag.
There are two additional clinical cautions in the policy that billing teams should flag for their clinical partners. First, patients with DBS implants must not be exposed to diathermy of any type (shortwave, microwave, or ultrasound diathermy) or MRI, which can damage the DBS system or injure surrounding brain tissue. Second, the policy requires extreme caution in patients with cardiac pacemakers or other electronically controlled implants that may interfere with or be affected by the DBS system. These aren't billing criteria, but documenting that the team addressed these risks supports medical necessity and protects against post-payment review.
Coverage Indications at a Glance
| Indication | DBS Target | Status | Notes |
|---|---|---|---|
| Essential tremor (postural/kinetic hand tremor, no other neurologic signs) | Thalamic VIM | Covered | Requires FTM scale ≥3–4, failed optimal medical therapy, patient cooperation |
| Idiopathic PD — tremor-dominant form (≥2 cardinal features) | Thalamic VIM | Covered | Same FTM and cooperation criteria as ET |
| Advanced idiopathic PD with ≥2 cardinal features | STN or GPi | Covered | Requires Hoehn & Yahr or UPDRS III, L-dopa responsiveness, persistent symptoms despite therapy |
| Non-idiopathic PD / "Parkinson's Plus" syndromes | Any | Not Covered | Absolute exclusion |
| PD with cognitive impairment, dementia, or depression | Any | Not Covered | Covered if condition would not worsen or interfere with benefit |
| PD/ET with current psychosis, alcohol, or drug abuse | Any | Not Covered | Absolute exclusion |
| Movement disorder from structural lesion (stroke, tumor, vascular malformation) | Any | Not Covered | Absolute exclusion |
| Prior movement disorder surgery in affected basal ganglion | Any | Not Covered | Absolute exclusion |
| Device used outside FDA approval and outside approved IDE trial | Any | Not Covered | Must confirm FDA approval status pre-implant |
| DBS in Category B IDE clinical trial | Any | Covered | Must follow FDA-approved IDE protocol |
CMS Deep Brain Stimulation Billing Guidelines and Action Items 2026
This policy has been in effect since April 1, 2003 at a base level, but this January 9, 2026 modification means your documentation templates and pre-authorization workflows need a fresh review right now. Here's what to do.
| # | Action Item |
|---|---|
| 1 | Audit your patient selection checklists against the updated NCD 279 criteria. Your pre-operative documentation must capture the specific elements CMS requires — FTM scale scores for VIM candidates, Hoehn & Yahr or UPDRS Part III for STN/GPi candidates, and documented levodopa response with defined "on" periods. If your intake forms don't capture these data points explicitly, update them before billing any DBS implantation claim dated on or after January 9, 2026. |
| 2 | Confirm FDA device approval status for every implant. The device used must be FDA-approved for DBS, or used under an FDA-approved Category B IDE protocol. Pull the FDA approval documentation for each DBS system your facility uses and keep it in the implant record. An auditor will ask for it. |
| 3 | Contact your MAC about prior authorization and local coverage determinations. NCD 279 sets the national floor, but your MAC may have a local coverage determination that adds prior authorization requirements or further restricts coverage in your region. Call or check your MAC's LCD database before the effective date — specifically before billing for cases scheduled after January 9, 2026. |
| 4 | Train your clinical documentation team on the six absolute exclusions. Every DBS candidate's chart needs a documented exclusion review. If a patient has any of the six contraindications and the surgeon proceeds anyway, the claim will be denied. There is no gray area in this policy on those exclusions. |
| 5 | Verify provider and facility credentialing against the policy's surgeon and facility requirements. NCD 279 requires that neurosurgeons be properly trained and experienced in the surgical management of DBS — and facilities must meet specific criteria as well. If your surgeons or facility haven't been credentialed against these standards recently, do it now. A claim submitted by a provider who doesn't meet the qualifications is not reimbursable, regardless of whether the patient met every clinical criterion. |
| 6 | Review and update your charge capture for DBS implantation procedures. NCD 279 does not list specific CPT or HCPCS codes. Ask your MAC or billing consultant which codes they recognize for lead implantation, pulse generator implantation, and programming for DBS procedures under this policy. Get that confirmed in writing and update your charge capture accordingly. Don't guess at codes when your MAC can tell you exactly what they'll process. |
| 7 | Consult your compliance officer if you're billing DBS for any condition outside ET or PD. NCD 279 is explicit: coverage is limited to ET, Parkinsonian tremor, and PD. If your program is exploring DBS for other indications — such as OCD or dystonia — those reimbursement pathways are governed by different coverage policy frameworks. Talk to your compliance officer before billing those cases under NCD 279. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Deep Brain Stimulation Under NCD 279
Specific Codes Listed in NCD 279
NCD 279 does not list specific CPT, HCPCS, or ICD-10 codes in the policy document. This is not unusual for an NCD — code-level guidance for deep brain stimulation billing is typically issued at the MAC level through local coverage determinations or LCDs, and through CMS billing guidelines published separately.
Your team should not infer or guess which codes to use. Contact your Medicare Administrative Contractor directly to confirm the current accepted CPT codes for DBS lead implantation, pulse generator implantation, and post-implant programming visits. Request this confirmation in writing and document it in your billing guidelines.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.